Gilead Sciences | GILD - Stock


Gilead Sciences reported $1.91B in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.13B 78M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
ALKERMES USD 298.96M 37.75M Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Coherus Biosciences USD 5.67M 842K Jun/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.16B 39M Mar/2026
Incyte USD 112.54M 3.08M Jun/2026
J&J USD 15.14B 561M Jun/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 280M 134M Jun/2026
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Novartis USD 6.22B 66M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
United Therapeutics USD 193.8M 15.5M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026